

MEDIA RELEASE

Cordlife launches new peripheral blood stem cell service in Singapore

- Cordlife is offering peripheral blood stem cell processing and storage service for patients in Singapore who require bone marrow (or haematopoietic) stem cells as part of their treatment for cancer or other disorders.

As part of the new service, Cordlife will process, test, and cryopreserve peripheral blood stem cells collected by clinic partners from patients who will need these stem cells for treatment.

- Haematopoietic stem cells (HSC) from peripheral blood can be used in bone marrow (or haematopoietic stem cell) transplants to treat patients with blood and immune system diseases affecting the bone marrow, such as leukaemia, myeloma, and lymphoma.
- Centre for Clinical Haematology will be Cordlife's first partner in the country to provide patients with the new peripheral blood stem cell service.

SINGAPORE, 24 FEBRUARY 2023 – Cordlife Group Limited ("**Cordlife**", together with its subsidiaries, the "**Group**"), a leading provider of cord blood banking services and a Singapore Exchange mainboard listed company, has announced the launch of their peripheral blood stem cell ("**PBSC**") processing and storage service in Singapore, further expanding its banking services in the country.

Centre for Clinical Haematology ("**CFCH**") will be Cordlife's first partner in the country to offer the new PBSC service to their patients who require haematopoietic stem cell transplantation as part of their treatment for blood cancers or other blood disorders. Peripheral blood is another source of blood-forming stem cells, also known as haematopoietic stem cells ("**HSC**"), which can be used in haematopoietic stem cell transplants ("**HSCT**") to treat cancers such as leukaemia, myeloma, and lymphoma, as well as other blood and immune system diseases affecting the bone marrow.

The aim of HSCT is to produce and replenish the blood system as well as to rebuild the immune system in patients who have had chemotherapy or radiotherapy, or have defective or damaged bone marrow. Currently, high-dose chemotherapy followed by an autologous HSCT is regarded as the standard of care for patients with multiple myeloma and Hodgkin and non-Hodgkin lymphomas. Autologous transplantation is when stem cells are taken from a patient's own blood, bone marrow, or cord blood and then put back into the same patient after treatment. If performed early in the course of the disease, HSCT is associated with better survival, less morbidity, and a better quality of life for the patient.

The collaboration involves CFCH evaluating, assessing, and determining patients' eligibility for a haematopoietic stem cell transplant ("**HSCT**") using their own PBSCs. Under the supervision of their multidisciplinary clinical team, CFCH will prepare their eligible patients for stem cell mobilisation and



harvesting. Cordlife will then take care of the rest of the process, including processing, testing, and the final cryopreservation of the PBSC.

"We are pleased to collaborate with Cordlife to provide this service," said Dr Lim Zi Yi, Medical Director of CFCH and Senior Consultant in Haematology. "Haematopoietic stem cell transplantation is an established and important form of treatment for blood cancers, and we believe that this service, combined with Cordlife's expertise in stem cell processing and cryopreservation, will help improve the outcomes for our patients."

Cordlife Group, as one of Asia's pioneers in the cryopreservation of umbilical cord blood obtained from babies, sees this partnership as another step towards expanding its cryopreservation expertise. Cordlife's Group CEO and Executive Director, Ms Tan Poh Lan said, "We are excited to work with CFCH and Dr Lim Zi Yi, who comes with more than two decades of experience in the field of haematology. Coupled with our 21 years of experience in the cryopreservation of biological samples, including cord blood, cord tissue, and corneal lenticules, our new PBSC service is yet another avenue for us to further our mission of providing more patients in Singapore with access to approved complementary medical treatment."

Cordlife has also appointed Dr Lim as the Group's medical director for the new PBSC service, owing to his extensive experience in haematology. Patients who are keen to know more about Cordlife's new PBSC service can reach out to CFCH. Cordlife will seek to collaborate with more doctors and healthcare institutions in Singapore to increase patient access to the PBSC service.

Centre for Clinical Haematology contact information:

<p>Mount Elizabeth Novena Specialist Centre 38 Irrawaddy Road #09-47/48/57 Singapore 329563 Tel: (65) 62568836</p>	<p>Gleneagles Hospital Annexe Block 6A Napier Rd #02-39/40 Singapore 258500 Tel: (65) 62613898</p>
--	--

End

ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group"), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia's largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia, and the Philippines and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, and cord tissue banking, Cordlife offers families a comprehensive suite of diagnostic services, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening.

Two of Cordlife's primary focus areas are providing reliable quality and being customer-centric. All of the Group's facilities are accredited by the Association for the Advancement of Blood &



Biotherapies (“AABB”), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two private cord blood banks in Asia and five worldwide to be accredited by both the AABB and the Foundation for the Accreditation of Cellular Therapy (“FACT”), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists (“CAP”). Healthbaby Hong Kong is the world's only private cord blood bank to be accredited by three international standard-setting bodies, and Cordlife India is one of only two medical laboratories in West Bengal to be accredited by the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ABOUT CENTRE FOR CLINICAL HAEMATOLOGY

Founded in 2019, Centre for Clinical Haematology (“CFCH”) is committed to providing quality care and working hard to prioritise patients’ health. The haematologists at CFCH are recognised internationally as experts in treating blood disorders. As part of their commitment to developing the field of haematology, they contributed to several medical boards and advisory groups. They are active in the field of clinical research and have published extensively in medical journals, as well as presented at key haematological conferences throughout the world.

A multidisciplinary team of doctors and skilled nurses work closely together with patients to guide them through their journey, ensuring that the patients are always kept well informed and involved in the decision-making process every step of the way. This is part of their treatment that is based on evidence and is designed to treat and care for patients and their families as a whole.

CFCH has two clinics in Singapore, located at Mount Elizabeth Novena Specialist Centre and Gleneagles Hospital. Both of these clinics provide professional and comfortable settings for patients to receive their personalised medical care, which is backed by state-of-the-art diagnostics and treatment. CFCH also has access to the inpatient haemato-oncology facilities at both of these hospitals.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Kamal Samuel / Ms Urvija Diwan

OFFICE : (65) 6438 2990

EMAIL : kamal@financialpr.com.sg / urvija@financialpr.com.sg